Thomas James Doyle, Senior Vice President of Finance and Accounting at Kura Oncology, Inc., filed a statement of changes in beneficial ownership on November 18, 2026, reporting a sell-to-cover transaction on November 16, 2026 tied to the vesting of performance-based restricted stock units.
Key Highlights
- Reporting person: Thomas James Doyle, SVP, Finance and Accounting at Kura Oncology, Inc. (NASDAQ:KURA)
- Shares disposed: 4,697 shares of common stock sold at $7.44 per share on November 16, 2026
- Purpose of sale: Sell-to-cover for taxes associated with the vesting of 1/6th of the underlying shares of performance-based restricted stock units granted on May 31, 2023
- Vesting trigger: The one-year anniversary of a specified development milestone was determined to have been met on November 13, 2026
- Post-transaction direct ownership: 138,081 shares of common stock held directly, plus 500 shares held indirectly through a spouse's 401(k)
- ESPP acquisition: 350 shares were acquired on November 17, 2026 pursuant to the issuer's Employee Stock Purchase Plan, included in the 138,081 total
Doyle's PSU Vesting Event and Share Sale at Kura Oncology
According to the filing, the disposition of 4,697 shares was a sell-to-cover transaction, meaning the shares were sold specifically to satisfy tax obligations arising from the vesting of equity awards rather than representing a discretionary open-market sale. The units involved were performance-based restricted stock units granted to Doyle on May 31, 2023. The filing states that each PSU "represents the contingent right to receive one share of the Issuer's common stock based on the achievement of each of three specified development milestones, and the one-year anniversary of each milestone achievement, subject to the Reporting Person's continuous service on each corresponding vesting date."
Kura Oncology is a clinical-stage biopharmaceutical company, and the PSU structure described in the filing directly links executive compensation to the achievement of development milestones, reflecting the company's stage of operations. The filing notes that the one-year anniversary of one such specified development milestone was determined to have been met on November 13, 2026, which triggered the vesting of 1/6th of the underlying PSU shares. The transaction was signed by Teresa Bair as attorney-in-fact for Thomas Doyle and filed on November 18, 2026. No derivative securities transactions were reported in Table II of the filing.
Following the reported transactions, Doyle beneficially owned 138,081 shares of common stock directly and 500 shares indirectly through a spouse's 401(k) account, according to the filing. The 138,081 direct share total includes 350 shares acquired on November 17, 2026 through the issuer's Employee Stock Purchase Plan, as noted in the filing's explanation of responses.
What Was Disclosed
The filing reported a November 16, 2026 sell-to-cover disposal of 4,697 common shares at $7.44 per share by Kura Oncology's SVP of Finance and Accounting, connected to PSU vesting triggered by a development milestone anniversary, leaving Doyle with 138,081 directly held shares.



Please wait processing your request...